Aktienanalyse zu IDEAYA Biosciences Inc (IDYA)IDYAIDEAYA Biosciences Inc

IDEAYA Biosciences, Inc. is a medicine oncology company. The Company is engaged in the discovery, development, and commercialization of transformative therapies for cancer. Its product candidates focus on synthetic lethality and antibody-drug conjugates (ADCs) for molecularly defined solid tumor indications. Its product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE161 (PARG), IDE275 (Werner Helicase) and IDE705 (Pol Theta Helicase). Darovasertib is a clinical stage, potent and selective small molecule inhibitor of PKC, a protein kinase that functions downstream of the GTPases GNAQ and GNA11. IDE397 is an oral small molecule inhibitor of methionine adenosyl transferase 2a (MAT2A). IDE161 is an oral small molecule poly (ADP-ribose) glycohydrolase (PARG) inhibitor. IDE275 is an oral small molecule inhibitor of the helicase domain of the Werner protein (WRN), a RecQ enzyme involved in the maintenance of genome integrity. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Currently, IDEAYA Biosciences Inc is not a strong buy due to its low RSI of 11.476, indicating oversold conditions, and a significant recent decline of 9.03% over the last 5 days. However, the forward P/E ratio of 4.649 suggests potential undervaluation, and analysts have set price targets as high as $63, indicating a possible upside of over 90% from the current price of $32.85. The primary risk is the recent negative performance and uncertainty around upcoming clinical trials, which could impact stock price significantly.